368 related articles for article (PubMed ID: 8858971)
1. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
2. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
3. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
4. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
5. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
6. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
7. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
Paronis CA; Woods JH
Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
9. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
Cahill CM; White TD; Sawynok J
J Pharmacol Exp Ther; 1995 Oct; 275(1):84-93. PubMed ID: 7562600
[TBL] [Abstract][Full Text] [Related]
10. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
11. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
12. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
13. Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography.
Morris BJ; Millan MJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):729-36. PubMed ID: 2846828
[TBL] [Abstract][Full Text] [Related]
14. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
15. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
[TBL] [Abstract][Full Text] [Related]
16. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
Bilsky EJ; Bernstein RN; Hruby VJ; Rothman RB; Lai J; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):491-501. PubMed ID: 8613959
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
18. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
Baumhaker Y; Gafni M; Keren O; Sarne Y
Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1992 Aug; 262(2):526-31. PubMed ID: 1380079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
